AVE1642 therapy, the antibody should be tested only in patients with MM that exhibits significant expression of CD221. Moreover, CD221 expression needs to be evaluated together with CD45 phenotype. 7, 8 CD45 is an important tyrosine phosphatase that can modulate signal transduction thresholds and impair the activation of the AKT pathway by IGF-1. 8 The lack of CD45 expression then allows a response to IGF-1, that is, growth through the AKT pathway. We have previously shown that AVE1642 was able to inhibit the proliferation of CD221 positive-CD45 negative, but not that of CD221 positive-CD45 positive human myeloma cell lines, and that the overexpression of CD221 in CD45-positive human myeloma cell lines was not sufficient to induce AVE1642 sensitivity. 4, 8 On the contrary, extinction of CD45 by shRNA in CD45 positive human myeloma cell lines was able to induce AVE1642 sensitivity. In the present study, CD45 phenotype was evaluated in 23 out of 26 patients, and was negative in 16 cases (70%). The second potential explanation is that AVE1642 was not able to neutralize insulin/IGF1 hybrid receptors. Indeed it has been shown that IGF1-R and insulin receptor can heterodimerize leading to the formation of insulin/IGF-1 hybrid receptors, which comprise one a-and one b-subunit of each receptor. A recent paper from Sprynski et al.
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML In the 2008 WHO (World Health Organization) classification, acute myeloid leukemia (AML) with inv(3)(q21q26)/t(3;3) (q21;q26) represents a distinct entity in the category 'AML with recurrent genetic abnormalities' 1 due to its specific clinical, morphological and genetic profile: cases show increased numbers of dysplastic megakaryocytes often with one or two nuclei, multilineage dysplasia and normal or elevated thrombocytes. Immunophenotypes are characterized by the expression of CD13, CD33, HLA-DR, CD34 and CD38 antigens, and by the aberrant coexpression of CD7, CD41 and CD61 as reported previously. 1 Additional cytogenetic abnormalities are common, the most frequent being monosomy 7. inv(3)(q21q26)/ t(3;3)(q21;q26) is associated with prognostically adverse upregulation of the EVI1 (ecotropic viral integration site 1 on 3q26.2) proto-oncogene. Juxtaposition of the RPN1 (Ribophorin) gene on 3q21 to EVI1 (on 3q26) was suggested to cause upregulation of EVI1 in inv(3)(q21q26)/t(3;3)(q21;q26) cases. Other cytogenetic subgroupsFsuch as AML with monosomy 7 or 11q23/MLL rearrangements 2 or with complex aberrant karyotypes 3 also show EVI1 overexpression. According to WHO, cases with t(8;21)(q22;q22)/RUNX1-RUNX1T1, inv(16)(p13q22)/CBFB-MYH11 or t(15;17)(q22;q12)/ PML-RARA are considered acute leukemias irrespective of blast counts. In contrast, according to WHO, cases with inv(3) (q21q26)/t(3;3)(q21;q26) and blasts o20% are categorized as myelodysplastic syndromes (MDSs). Whether this is reasonable has to be evaluated further, and the profiles of associated molecular markers in AML or MDS with inv(3)(q21q26)/t(3;3) (q21;q26) remain to be investigated. To clarify these questions, we analyzed 39 cases of AML (n ¼ 23) or MDS (n ¼ 16) with an inv(3)(q21q26)/t(3;3)(q21;q26) selected from our database for additional cytomolecular and molecular markers and for the clinical profiles independent of the morphological categories: 20 females and 19 males at a median age of 64. All cases were investigated by a chromosome banding analysis. Fluorescence in situ hybridization was performed for NF1 (neurofibromatosis type 1) deletions (cutoff level: 3%), and molecular analysis was performed for NPM1, FLT3-TKD/-ITD, MLL-PTD, KRAS/NRAS, RUNX1, KITD816, IDH1, CBL, JAK2V617F and MPLW515 in all cases with available material according to published methods. The sensitivity of the mentioned PCR-based methods was at least 5%. In addition, EVI1 expression was measured by quantitative reverse transcriptase-PCR in 28 cases (21 AML (17 de novo AML, 2 secondary AMLs, 2 t-AMLs (therapy-related AML)) and 7 MDS). 4 The EVI1 expression did not differ between AML and MDS (mean ± s.d.: AML: 101.6 ± 98.8; MDS: 80.2 ± 73.3).
Cytomorphological diagnoses of 39 patients were distributed as follows: 23 patients had AML (18 de novo, 2 t-AMLs, 1 secondary AML after MDS and 2 secondary AML after myeloproliferative neoplasms) and 16 had MDS (15 de novo and 1 t-MDS). Thus, inv(3)(q21q26)/t(3;3)(q21;q26) occurs in MDS, and AML of de novo or secondary/therapy-associated origin.
inv(3)(q21q26) and t(3;3)(q21;q26) were present in 26 and 13 cases, respectively. Additional chromosomal alterations were detected in 24 of 39 patients (61.5%), more frequently in AML than in MDS (16/23; 69.6% vs 8/16; 50.0%; NS). Corresponding to previous reports, 1, 5 aberrations most frequently affected chromosome 7 (16/39 cases; 41.0%; of the total cohort; in detail: isolated À7: n ¼ 11; chromosome 7 alterations plus others: n ¼ 4; del(7q): n ¼ 1). Chromosome 5 alterations were observed in six cases (Table 1 and Supplementary Table S1 Specifying on the different cytomorphological cohorts, alterations of KRAS, NF1 and RUNX1 were more frequent in AML than in MDS patients (KRAS: 6/18; 33.3% in AML vs 0/7; 0% in MDS; NF1: 3/15; 20.0% vs 0/9; 0%; RUNX1: 5/20; 25.0% vs 1/9; 11.1%; JAK2V617F: 1/21; 4.8% vs 0/9; 0%), but statistical significance was not reached. NRAS, CBL and IDH1 mutations were more frequent in MDS patients (NRAS: 3/10, 30.0%; CBL: 1/9, 11.1%; IDH1: 1/8; 12.5%) than in AML patients (NRAS: 4/20, 20.0%; CBL: 2/19, 10.5%; IDH: 0/16) (NS). Therefore, 34 patients were investigated by chromosome banding and molecular analyses in parallel: 29 of 34 patients (85.3%) had additional chromosomal and/or molecular alterations. The occurrence of additional aberrations, either cytogenetic or molecular genetic, was more frequent in AML than in MDS (AML: 21/22; 95.5%; MDS: 8/12; 66.7%; P ¼ 0.042). Both additional chromosomal and molecular alterations were seen in 11 of 34 (32.4%) patients, with a higher frequency in AML (MDS: 1/12; 8.3%; AML: 10/22; 45.5%; P ¼ 0.05).
In a previous study, we had observed a high frequency of NRAS mutations in AML with inv(3)(q21q26)/t(3;3)(q21;q26) (26.8%) and inv(16)/CBFB-MYH11 (37.6%). 6 The NF1 gene encodes neurofibromin 1, a negative regulator of the RAS pathway and a potential tumor-suppressor gene. Recently, NF1 deletions were shown in 16.2% of 37 AML cases with inv(16)/ CBFB-MYH11. 7 Thus, inv(3)(q21q26)/t(3;3)(q21;q26) and other inversions/reciprocal intra-chromosomal translocations seem to specifically cooperate with RAS-activating alterations (such as NRAS, KRAS, NF1), whereas other mutations such as NPM1 or FLT3 show no coincidence with inv(3)(q21q26)/t(3;3)(q21;q26). Specific cooperation pathways have also been observed in other AML subtypes: for example, t(15;17)/PML-RARA shows frequent coincidence with FLT3 mutations, whereas NRAS mutations are underrepresented.
Clinical outcome (overall survival (OS) and event-free survival) did not differ significantly between the 13 MDS and 20 AML cases (including 16 de novo AML and 4 s-/t-AMLs) with follow-up data (Figure 1a ). In addition, no differences in OS and event-free survival were observed between cases with inv(3)(q21q26) (n ¼ 23) and t(3;3)(q21;q26) (n ¼ 10). Subsequently, the de novo AML cases with inv(3)(q21q26)/ t(3;3)(q21;q26) were analyzed in the context of 814 de novo AML without inv(3)/t(3;3) (s-/t-AMLs were excluded for this analysis). The median OS for the total cohort was 48.2 months, and the median event-free survival was 16.3 months. Cases were subdivided in 8 cytogenetic subgroups: (1) t(15;17)(q22;q21) (n ¼ 48), (2) t(8;21)(q22;q22) (n ¼ 29), (3) inv(16)(p13q22)/t(16;16) (p13;q22) (n ¼ 19), (4) 11q23/MLL rearrangements (n ¼ 11), (5) inv(3)(q21q26)/t(3;3)(q21;q26) (n ¼ 16), (6) normal karyotype (n ¼ 425), (7) complex aberrant karyotypes (n ¼ 71) (a complex karyotype was defined as a karyotype showing X4 unrelated abnormalities) and (8) Letters to the Editor for groups 5, 7 and 8, respectively (median event-free survival: groups 1-2: not reached; groups 3-8: 15.9, 13.5, 6.3, 16.0, 7.5 and 12.5 months (Figures 1b and c) ). Thus, the OS of AML with inv(3)(q21q26)/t(3;3)(q21;q26) was similar to complex aberrant AML. Many cytogenetic studies did not specify on outcomes of AML with inv(3)(q21q26)/t(3;3)(q21;q26), but combined this subtype with other rare or unfavorable alterations. According to a recent Medical Research Council (MRC) study, the 10-year OS rate was 3% and the cumulative incidence of relapse was 89% in patients with AML and inv(3)(q21q26)/t(3;3)(q21;q26), 4 and Lugthart et al. 5 described a 5-year OS of 5.7% in these patients. Weisser et al. 8 suggested that the prognosis of patients with an inv(3)(q21q26)/t(3;3)(q21;q26) was significantly improved by allogeneic hematopoietic stem cell transplantation.
In summary, the AML cohort with inv(3)(q21q26)/ t(3;3)(q21;q26) showed higher frequencies of additional cytogenetic and molecular mutations than did MDS patients. As most cases (85.3% of the total cohort) had additional cytogenetic and/or molecular genetic abnormalities, inv(3)(q21q26)/ t(3;3)(q21;q26) seems unable to induce leukemogenesis without the support of other genetic alterations. The prognosis of patients with inv(3)(q21q26)/t(3;3)(q21;q26) is unfavorable both in MDS and in AML. Therefore, our data support to classify cases with an inv(3)(q21q26)/t(3;3)(q21;q26) as AML irrespective of blast count comparable with the WHO categories AML t(8;21) (q22;q22)/RUNX1-RUNX1T1, inv(16)(p13q22)/t16;16)(p13;q22)/ CBFB-MYH11 or t(15;17)(q22;q12)/PML-RARA. Cooperation with RAS-activating mutations is frequent in myeloid malignancies with an inv(3)(q21q26)/t(3;3)(q21;q26). Developing this and published data to a perspective targeting the RAS pathway might be a promising therapeutic approach in this AML subtype. 
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